I 

118TH CONGRESS 

2D SESSION H. R. 8570 

To establish a pharmacy program to award grants for safe in-home drug 

disposal and practical medication safety education, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

MAY 24, 2024 

Mr. HUDSON introduced the following bill; which was referred to the 

Committee on Energy and Commerce 

A BILL 

To establish a pharmacy program to award grants for safe 

in-home drug disposal and practical medication safety 

education, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Safe In-Home Drug 

5 Disposal Initiative Act of 2024’’ or the ‘‘SIDDI Act of 

6 2024’’. 

7 SEC. 2. SAFE IN-HOME DRUG DISPOSAL INITIATIVE. 

8 (a) IN GENERAL.—Not later than 180 days after the 

9 date of enactment of this Act, the Secretary of Health and 

10 Human Services, acting through the Assistant Secretary 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 8570 IH

1 for Mental Health and Substance Use, (in this section re2 ferred to as the ‘‘Secretary’’) shall establish a program 

3 to award grants to States to implement targeted State 

4 demonstration initiatives (in this section referred to as 

5 ‘‘TSDIs’’). Such TSDIs shall reimburse licensed phar6 macies that choose to participate in the TSDI (in this sec7 tion referred to as ‘‘participating pharmacies’’) for the 

8 provision to eligible patients, in coordination with the de9 livery of drug prescriptions, of in-home drug disposal sys10 tems and standard medication safety education. 

11 (b) APPLICATION.—To be eligible to receive a grant 

12 under this section, a State shall submit to the Secretary 

13 an application at such time, in such manner, and con14 taining such information as the Secretary may require. 

15 Such an application shall— 

16 (1) identify the State agency that oversees 

17 pharmaceutical care and will be responsible for ad18 ministering a TSDI through a grant under this sec19 tion; 

20 (2) identify the single pharmacy benefit man21 ager (commonly known as a ‘‘PBM’’) that will be re22 sponsible for— 

23 (A) adjudicating claims under the TSDI; 

24 (B) reimbursing participating pharmacies; 

25 and 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
3 

•HR 8570 IH

1 (C) facilitating the type of customization 

2 required to successfully administer a custom, 

3 fully transparent program, with pass-through 

4 claims adjudication services benefitting pa5 tients, plans, and pharmacies; 

6 (3) outline the process by which participating 

7 pharmacies will submit usual and customary costs 

8 related to the reimbursement and remuneration of 

9 services, including detailed reporting on— 

10 (A) criteria of patient selection; 

11 (B) initial activity; and 

12 (C) patient engagement factors; 

13 (4) detail the process through which standard 

14 medication safety education will be communicated by 

15 each participating pharmacist or pharmacy techni16 cian at the point of dispensing, allowing for unique 

17 needs and education to be tailored for State-, coun18 ty-, town-, and municipality-specific needs; 

19 (5) detail a plan to increase participation rates 

20 of pharmacists and pharmacy technicians through a 

21 single electronic pharmacy claim process; 

22 (6) state the remuneration amounts for the pro23 vision of standard medication safety education, and 

24 the reimbursement amounts for in-home drug dis25 posal systems, which for each eligible patient shall 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
4 

•HR 8570 IH

1 be assessed separately but processed through a sin2 gle electronic claim; 

3 (7) describe how the State will select phar4 macies to be served under the TSDI; and 

5 (8) include the number of eligible patients to be 

6 served under the TSDI. 

7 (c) NUMBER.—The Secretary shall award grants 

8 under this section to not more than 5 States. 

9 (d) GRANT PERIOD.—A grant awarded under this 

10 section shall be for a period of at least 3 years. 

11 (e) ACCOUNTABILITY AND OVERSIGHT.—As a condi12 tion of receiving a grant under this section, a State shall 

13 agree to submit to the Secretary, at such time and in such 

14 manner as the Secretary may reasonably require, a report 

15 on the TSDI of the State implemented through such 

16 grant. Such report shall— 

17 (1) list the number of pharmacy locations that 

18 are reimbursed through the grant funds; 

19 (2) describe the activities undertaken by the 

20 State using the grant amounts, outlining the in21 home drug disposal solutions distributed and the pa22 tient education delivered; 

23 (3) survey pharmacies to collect demographic 

24 information on participating patients, medication 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
5 

•HR 8570 IH

1 types prescribed, and the effective use of the in2 home drug disposal systems; and 

3 (4) contain performance measures relating to 

4 the effectiveness of the grant, including changes in 

5 the participation rate of eligible patients and the en6 gagement with pharmacists. 

7 (f) DEFINITIONS.— In this section: 

8 (1) ELIGIBLE PATIENTS.—The term ‘‘eligible 

9 patients’’ means patients receiving an opioid pre10 scription who are at risk of experiencing an opioid11 related overdose, including such patients— 

12 (A) with a first-time opioid prescription; 

13 (B) with an acute opioid prescription pre14 scribed for a short-term illness or condition; or 

15 (C) that have received a change in the 

16 opioid dosage of an acute or chronic opioid pre17 scription. 

18 (2) IN-HOME DRUG DISPOSAL SYSTEM.— The 

19 term ‘‘in-home drug disposal system’’ means a sys20 tem of drug disposal— 

21 (A) that changes the physical integrity of 

22 the formulation of a drug; 

23 (B) that renders the active ingredients of 

24 such drug unusable for all practical purposes; 

25 (C) that— 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
6 

•HR 8570 IH

1 (i) is nontoxic and nonhazardous; 

2 (ii) poses no threat to the consumer; 

3 and 

4 (iii) reduces drug exposure to the en5 vironment; and 

6 (D) that acts as a deterrent for misuse of 

7 drugs. 

8 (3) STANDARD MEDICATION SAFETY EDU9 CATION.—The term ‘‘standard medication safety 

10 education’’ means medication safety education— 

11 (A) provided by a pharmacist or pharmacy 

12 technician to eligible patients for a duration of 

13 not more than 5 minutes per patient; and 

14 (B) that includes information relating to— 

15 (i) proper medication storage; 

16 (ii) risks associated with keeping un17 used medication in the home; 

18 (iii) proper in-home disposal of un19 used medication; and 

20 (iv) in the case of naloxone that is 

21 prescribed as an opioid medication, the 

22 proper use of such naloxone 

23 (4) STATE.—The term ‘‘State’’ means each of 

24 the several States, the District of Columbia, and any 

25 territory of the United States. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
7 

•HR 8570 IH

1 (g) AUTHORIZATION OF APPROPRIATIONS.—There is 

2 authorized to be appropriated to carry out this section 

3 $56,000,000 for the period of fiscal years 2025 through 

4 2029. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB